Cline Scientific AB adds new orthopedic center to StemCART project
Cline Scientific AB announces that they have begun a partnership with Sahlgrenska University Hospital, orthopedics, for the collection and testing of human knee cartilage tissue as part of the StemCART project.
During 2022, Cline has been conducting exvivo tests on samples in collaboration with Varberg Hospital and orthopedic surgeons. The addition of a second hospital, Sahlgrenska University Hospital allows Cline more opportunity for conducting studies, in particular for knee cartilage, essential for the next phase of preclinical tests of StemCART.
More about StemCART
StemCART is a preclinical Advanced Therapy Medical Product (ATMP) that aims to revolutionize the treatment of cartilage damage for patients worldwide. To achieve this, Cline will continue preparing for in-human clinical trials, including scaling up production into a GMP facility, developing QA/QC methods, and the necessary safety testing and documentation for a clinical trial application. Cline envisions out-licensing StemCART to a commercial partner following successful phase I trials.
For more information, please contact:
Patrik Sundh, CEO
Email: [email protected]
Phone: +46 703-585 088
About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline’s unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.
Iconovo AB has completed a directed new share issue of SEK 55 million
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, DISTRIBUTION OR RE...
Iconovo AB har genomfört en riktad nyemission om 55 miljoner SEK
EJ FÖR PUBLICERING, DISTRIBUTION, ELLER OFFENTLIGGÖRANDE, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, USA ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDAN HANDLING SKULLE VARA FÖRBJUDEN ENLIGT LAG ELLER KRÄVA...
CLS Americas and HALO Precision Diagnostics Announce 25 Patient Post-Market Study to Evaluate CLS’s TRANBERG Thermal Therapy System
IRVINE, Calif. and INDIAN WELLS, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, and HALO Precision Diagnostics, Inc. (HALO), today announced a Letter of Intent to e...
Clinical Laserthermia Systems signs LOI with HALO Precision Diagnostics for TRANBERG Thermal Therapy System
Lund, Sweden – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) today announces that their US subsidiary CLS Americas has signed a Letter of Intent (LOI) with HALO Precision Diagnostics, Inc. (HALO) for evaluation of safety and short term efficacy of CLS’s TRANBERG® Thermal Therapy S...